RICHLAND, Wash., April 29, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference ...
RICHLAND, WA--(Marketwired - Jun 30, 2014) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for cancers of the ...
RICHLAND, Wash.--(BUSINESS WIRE)-- IsoRay, Inc. (Amex: ISR) announced, today, it has completed an initial feasibility study, which demonstrates the ability to use its patented Cesium-131 (Cs-131) ...
RICHLAND, Wash., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a ...
Investors might want to bet on IsoRay (ISR), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...
RICHLAND, Wash., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout ...
RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing ...
RICHLAND, Wash., May 12, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR) today announced that the Centers for Medicare and Medicaid Services (CMS) has approved 64 ICD-10-PCS billing codes ...
RICHLAND, Wash., Jan. 7, 2016 /PRNewswire/ -- IsoRay Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of ...
In fiscal year 2010, 97% of revenue was generated from the sales of Proxcelan TM Cesium-131 brachytherapy seeds for the treatment of prostate cancer while the other 3% of revenue was generated by ...
The company's growth has stalled and its costs are increasing and it doesn't look like a dramatic reverse is in sight anytime soon. Viewpoint is promising but years off from generating revenues and ...
RICHLAND, Wash., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results